Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases. The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase I clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a strategic licensing and collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone408-973-7884
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$220,000.00
Profitability
Miscellaneous
Employees193
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions
What is Cellular Biomedicine Group's stock symbol?
Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."
How will Cellular Biomedicine Group's stock buyback program work?
Cellular Biomedicine Group announced that its board has initiated a stock repurchase program on Sunday, June 4th 2017, which authorizes the company to buyback $10,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board believes its stock is undervalued.
How were Cellular Biomedicine Group's earnings last quarter?
Cellular Biomedicine Group Inc (NASDAQ:CBMG) posted its quarterly earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.01. The biotechnology company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.05 million. Cellular Biomedicine Group had a negative return on equity of 42.41% and a negative net margin of 17,921.62%. View Cellular Biomedicine Group's Earnings History.
When is Cellular Biomedicine Group's next earnings date?
What price target have analysts set for CBMG?
3 Wall Street analysts have issued 12 month price targets for Cellular Biomedicine Group's shares. Their forecasts range from $26.00 to $38.00. On average, they expect Cellular Biomedicine Group's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 85.0% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.
What is the consensus analysts' recommendation for Cellular Biomedicine Group?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.
Has Cellular Biomedicine Group been receiving favorable news coverage?
News articles about CBMG stock have trended somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cellular Biomedicine Group earned a news impact score of -1.2 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Cellular Biomedicine Group's key competitors?
Some companies that are related to Cellular Biomedicine Group include Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), NanoString Technologies (NSTG), Autolus Therapeutics (AUTL), GENFIT S A/ADR (GNFT), BioCryst Pharmaceuticals (BCRX), Voyager Therapeutics (VYGR), MeiraGTx (MGTX), Cellectis (CLLS), Nightstar Therapeutics (NITE), Twist Bioscience (TWST), Vericel (VCEL) and Precision BioSciences (DTIL).
What other stocks do shareholders of Cellular Biomedicine Group own?
Who are Cellular Biomedicine Group's key executives?
Cellular Biomedicine Group's management team includes the folowing people:
- Mr. Bizuo Liu, CEO, CFO & Director (Age 54)
- Dr. Yihong Yao, Chief Scientific Officer (Age 51)
- Mr. Andrew K. Chan, Chief Legal Officer, Gen. Counsel, Sr. VP of Corp. Bus. Devel. & Sec. (Age 61)
- Dr. Li Zhang, Chief Production Officer
- Derrick C. Li, Head of Strategy & Investor Relations
Who are Cellular Biomedicine Group's major shareholders?
Cellular Biomedicine Group's stock is owned by a number of of institutional and retail investors. Top institutional investors include Platinum Investment Management Ltd. (3.61%), BlackRock Inc. (3.57%), Nikko Asset Management Americas Inc. (2.15%), Sumitomo Mitsui Trust Holdings Inc. (2.12%), ARK Investment Management LLC (1.58%) and Charles Schwab Investment Management Inc. (0.14%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.
Which institutional investors are selling Cellular Biomedicine Group stock?
Which institutional investors are buying Cellular Biomedicine Group stock?
CBMG stock was bought by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., ARK Investment Management LLC, Wells Fargo & Company MN, State of Wisconsin Investment Board, California Public Employees Retirement System and BNP Paribas Arbitrage SA. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.
How do I buy shares of Cellular Biomedicine Group?
Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellular Biomedicine Group's stock price today?
One share of CBMG stock can currently be purchased for approximately $17.30.
How big of a company is Cellular Biomedicine Group?
Cellular Biomedicine Group has a market capitalization of $312.96 million and generates $220,000.00 in revenue each year. The biotechnology company earns $-38,930,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. Cellular Biomedicine Group employs 193 workers across the globe.
What is Cellular Biomedicine Group's official website?
How can I contact Cellular Biomedicine Group?
Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]
MarketBeat Community Rating for Cellular Biomedicine Group (NASDAQ CBMG)
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe CBMG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days.
